Raloxifene: Difference between revisions
Jump to navigation
Jump to search
imported>Tom Morris No edit summary |
imported>Meg Taylor No edit summary |
||
Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
In [[pharmacology]], '''raloxifene''' is "a second generation [[selective estrogen receptor modulator]] (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and [[cholesterol]] metabolism but behaves as a complete [[estrogen]] antagonist on mammary gland and uterine tissue."<ref>{{MeSH}}</ref> | |||
In [[pharmacology]], '''raloxifene''' is "a second generation [[selective estrogen receptor modulator]] (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist | |||
==External links== | ==External links== | ||
Line 7: | Line 6: | ||
==References== | ==References== | ||
{{reflist}} |
Latest revision as of 02:15, 7 October 2013
![](http://s9.addthis.com/button1-share.gif)
In pharmacology, raloxifene is "a second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue."[1]
External links
The most up-to-date information about Raloxifene and other drugs can be found at the following sites.
- Raloxifene - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Raloxifene - Drug information for consumers from MedlinePlus (U.S. National Library of Medicine).
- Raloxifene - Detailed information from DrugBank.
References
- ↑ Anonymous (2024), Raloxifene (English). Medical Subject Headings. U.S. National Library of Medicine.